- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Medical Research
Lilly's Alzheimer’s effort may gain from brain-mapping plan
February 18, 2013
Bloomberg NewsRoche AG and Eli Lilly and Co., two drugmakers racing to develop treatments for some of the least understood brain disorders,
may gain the most from a U.S. government boost in funding to fully map the human brain.
MoreIndy loses promising health startup
November 12, 2012
J.K. WallLabDoor, which soon will launch an iPhone app that assigns A-F grades to over-the-counter vitamins and medicines, moved last
month from Indianapolis to San Francisco, where it received $100,000 in startup financing.
MoreLilly CEO calls for life sciences research institute
October 23, 2012
J.K. WallEli Lilly CEO John Lechleiter on Tuesday called for creation of a "world-class" research institute in Indianapolis to bring
together scientists from universities and corporations to develop new medical therapies and companies.
MoreAlzheimer’s prevention seen promising as drug cures fail
October 19, 2012
Bloomberg NewsResearchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts
to find a cure have been unsuccessful.
MoreSledge's exit will keep IU program mostly intact
October 1, 2012
J.K. WallThe departure of Dr. George Sledge likely will sap the breast cancer research program at the Indiana University Melvin and
Bren Simon Cancer Center of about $500,000 in annual funding. But the program Sledge built over the past three decades mostly
will remain intact.
MorePurdue health care engineering center lands another $10M
September 12, 2012
J.K. WallPurdue University’s Regenstrief Center for Healthcare Engineering will get another $10 million from the Indianapolis-based
Regenstrief Foundation, keeping its research going through 2018.
MoreAlzheimer's quest puts Lilly to test
August 11, 2012
J.K. WallOdds are long that Eli Lilly and Co.'s leading Alzheimer's drug will show positive results when its Phase 3 trial results
are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a
home run for Lilly.
MoreDespite funding dip, IU bets on brains
August 6, 2012
J.K. WallThe city that brought the world Prozac and other neuroscience drugs is doubling down on brain research with a new $52 million
research center near Methodist Hospital.
MoreIndiana Blood Center tapping new vein of revenue
July 28, 2012
Mason KingGroup sees role in cellular therapy as growth area with profit margins higher than core business.
MoreIU research leads to new genetic test
June 4, 2012
J.K. WallIt took the identification of 19 different genes for researchers at the Indiana University School of Medicine to develop a test for a rare form of cancer. But their gene-hunting has paid off, as a Texas-based company announced Monday the test is available for doctors to use.
NFP of NOTE: Cornea Research Foundation of America
May 19, 2012
The Cornea Research Foundation of America is a not-for-profit clinical research organization dedicated to the preservation
and restoration of vision.
MoreU.S. losing drug-research jobs to other countries
May 17, 2012
Bloomberg NewsEli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore,
Ireland and South Africa boost incentives.
MoreBioCrossroads has stoked state's life sciences industry, but challenges remain
February 11, 2012
J.K. WallIn the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies,
an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national
reports on life sciences.
MoreQ&A
December 27, 2011
J.K. WallDr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.
IU med school gets $9M for Alzheimer's center
November 1, 2011
J.K. WallThe grant is the fifth consecutive five-year grant the Alzheimer Disease Center has received from NIH to support research
to understand the causes and potential treatments for Alzheimer’s and other forms of dementia.
MoreLilly fights view that fate hinges on Alzheimer's drug
October 29, 2011
Greg AndrewsAnalysts have eyes on trial data for drug that could be a game-changer for the company.
MoreIU Cancer Center recruits top researcher
September 15, 2011
Scott OlsonDr. Murray Korc, an internationally known pancreatic cancer researcher, comes to the cancer center as the first Myles Brand
Professor of Cancer Research. The position is funded through a Lilly Endowment grant.
MoreHealth regulatory leaders ready to flock to city
September 14, 2011
IBJ StaffThe top event for regulatory professionals in the health care industry is headed to Indianapolis next month. The annual conference
of the Regulatory Affairs Professionals Society, or RAPS, is expected to draw thousands of members representing 120 companies
and organizations.
MoreEli Lilly's Elanco unit blossoming at just the right time
July 30, 2011
Greg AndrewsAn investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass
$3 billion by 2018.
MorePrimary care gets a new approach: prevention
July 20, 2011
Associated PressA budding model for primary care that encourages the family doctor to act as a health coach who focuses as much on preventing
illness as on treating it has shown promising results and saved insurers millions of dollars.
MoreRoche wins as high court limits university patent rights
June 6, 2011
Bloomberg NewsMonday's Supreme Court decision is a victory for companies that collaborate with universities in research. Indianapolis-based
Eli Lilly and Co. was among the companies that supported Roche.
MoreBrain barrier breached in push to deliver Alzheimer's drug
May 25, 2011
Scientists with Roche Holding AG, the parent company of Indianapolis-based Roche Diagnostics Corp., may have found a way to
overcome a blood barrier that keeps drugs from directly entering the brain, potentially opening new pathways to attack Alzheimer’s
disease.
MoreChina making big gains in drug R&D jobs state covets
April 9, 2011
Greg AndrewsThe total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is
one-third of that, said a company executive.
MoreResearch jobs could flow from Purdue quad
March 19, 2011
Marc D. AllanPurdue University officials and others connected with the life sciences in Indiana say the planned $164 million Life and Health
Sciences Quadrangle at the West Lafayette campus will mean high-paying jobs, retention of highly skilled scientists, and researchers
who might well have left the state for either coast.
MoreRegulators delay approval of Lilly's Alzheimer’s screen
March 18, 2011
Bloomberg NewsThe Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
See, I told u Indyman and Dipsicle....this 8 days is overkill. It's barely worth a weekend....great job Tony George! Your dream has been fulfilled....he fans want the I r l back. Thats how good it was.....and that sucked.
I have been in training for a short time now but right off I can see that safety and quality are the number one issues, my experience as of late has been a positive one, the employees along with Jeff the plant manager and the operation supervisor as well as the engineers are a highly motivated group of people, what an asset for the area to have and for company's in need of a quality metal products.
Pimlico
While I understand the severity of their actions as well as everyones eagerness to hold them responsible for thier lost funds, these gentlemen did know how to make money. Dispite thier poor decisions over the ownership of Fair they had made several wise investments which paid them greatly. This proves they do have the potential to rebuild so they can repay. I do not feel they should live the life of luxuary but given an opportunity could they find ways of repaying the debts? They are doing nothing now but being a burden on tax payers. Just a thought!!!!!
You guys have some "interesting" comments to say the least. I hope you will call in and share those opinions starting June 1. I'm looking forward to having you on the air.